Evidence map›Paper›PMID 24723983›Full record

ArticleTheranostics2014

Polyacrylamide-based biocompatible Nanoplatform enhances the tumor uptake, PET/fluorescence imaging and anticancer activity of a chlorophyll analog.

Anurag Gupta, Shouyan Wang, Aimee Marko, Penny Joshi, Manivannan Ethirajan, Yihui Chen, Rutao Yao, Munawwar Sajjad, Raoul Kopelman, Ravindra K Pandey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Intracellular Photodynamic Activity of Chlorin e6 Containing Nanoparticles.International journal of nanomedicine and nanosurgery · 2016
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Anurag Gupta1. PDT Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;
Shouyan Wang2. Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA;
Aimee Marko1. PDT Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;
Penny Joshi1. PDT Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;
Manivannan Ethirajan1. PDT Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;
Yihui Chen1. PDT Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;
Rutao Yao3. Department of Nuclear Medicine, State University of New York, Buffalo, NY 14032, USA.
Munawwar Sajjad3. Department of Nuclear Medicine, State University of New York, Buffalo, NY 14032, USA.
Raoul Kopelman2. Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA;
Ravindra K Pandey1. PDT Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;
Roswell Park Comprehensive Cancer Center · USUniversity of Michigan–Ann Arbor · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Christine B. Ambrosone · 1985 to 2026
$116.6M
Multifunctional Photosensitizers for Image-guided PDT of Brain TumorsR01CA127369 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI PANDEY, RAVINDRA K. · 2008 to 2012
$3.0M
NCI NIH HHS P30 CA016056NCI NIH HHS P30CA16056NCI NIH HHS R01 CA127369
6 · The paper itself

Abstract

In this report we demonstrate the outstanding advantages of multifunctional nanoplatforms for cancer-imaging and therapy. The non-toxic polyacrylamide (PAA) nanoparticles (size:18-25 nm) formulation drastically changed the pharmacokinetic profile of the ¹²⁴I- labeled chlorophyll-a derivative (formulated in 10% ethanol in PBS) with a remarkable enhancement in tumor uptake, and significantly reduced uptake in spleen and liver. Among the various nanoformulations investigated, the ¹²⁴I- labeled photosensitizer (dose: 0.6142 MBq), and the cyanine dye-nanoparticles (CD-NP) conjugate (dose 0.3 μmol/kg) in combination showed great potential for tumor imaging (PET/NIR fluorescence) in BALB/c mice bearing Colon26 tumors. Compared to free non-labeled photosensitizer, the corresponding PAA nanoformulation under similar treatment parameters showed a remarkable enhancement in long-term tumor cure by PDT (photodynamic therapy) and provides an opportunity to develop a single nanoplatform for tumor-imaging (PET/fluorescence) and phototherapy, a practical "See and Treat" approach.

Indexed as

PhotochemotherapyPositron-Emission TomographyAnimalsChlorophyllColonic NeoplasmsIodine RadioisotopesMiceMice, Inbred BALB CNanoparticlesPhotosensitizing AgentsTomography, OpticalChlorophyllIodine Radioisotopesmethyl 3-(1'-3-iodobenzyloxyethyl)-3-devinylpyropheophorbide-aPhotosensitizing AgentsNanoparticlesphotodynamic therapyPositron Imaging TomographyReactive Oxygen species.

Identifiers

PMID24723983
PMCPMC3982132
OpenAlexW2043704542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.